Increasing the α 2, 6 Sialylation of Glycoproteins May Contribute to Metastatic Spread and Therapeutic Resistance in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Abnormal glycosylation due to dysregulated glycosyltransferases and glycosidases is a key phenomenon of many malignancies, including colorectal cancer (CRC). In particular, increased ST6 Gal I (β-galactoside α 2, 6 sialyltransferase) and subsequently elevated levels of cell-surface α 2, 6-linked sialic acids have been associated with metastasis and therapeutic failure in CRC. As many CRC patients experience metastasis to the liver or lung and fail to respond to curative therapies, intensive research efforts have sought to identify the molecular changes underlying CRC metastasis. ST6 Gal I has been shown to facilitate CRC metastasis, and we believe that additional investigations into the involvement of ST6 Gal I in CRC could facilitate the development of new diagnostic and therapeutic targets. This review summarizes how ST6 Gal I has been implicated in the altered expression of sialylated glycoproteins, which have been linked to CRC metastasis, radioresistance, and chemoresistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683 · cited 2×
“EGFR is a transmembrane glycoprotein that has an extracellular ligand binding domain and an intracellular tyrosine kinase domain; it acts as a receptor tyrosine kinase and mediates cellular responses to growth factor through the RAS, signal transduction and activator of transcription, and PI3K/AKT pathways.(135) Studi…”
BackgroundImaging hypoxia to improve radiotherapy outcome
Horsman, M. R., Mortensen, L. S., Petersen, J. B., Busk, M., & Overgaard, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.171 · Cited by 614
A two-way street: reciprocal regulation of metabolism and signalling
Wellen, K. E., & Thompson, C. B. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3305 · Cited by 528 · cited 1×
“In the context of posttranslational modification and cancer metabolism, glycosylation (including sialylation) is known to play a crucial role at the interface between metabolism and signaling in cancer.(151) A number of carbohydraterelated genes, including those encoding fucosyltransferase VII, b-galactoside a-2, 3-si…”
BackgroundImplications for KRAS status and EGFR-targeted therapies in metastatic CRC
Normanno, N., Tejpar, S., Morgillo, F., De Luca, A., Van Cutsem, E., & Ciardiello, F. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.111 · Cited by 436 · cited 4×
“Similarly, sequencing of the EGFR exons in human CRC cell lines (e.g., SW620, SW480, CaCo-2, HCT116, and HT- 29) failed to identify any mutation of EGFR.141 The sensitivity of CRC to EGFR TKIs was not found to be dependent upon p53 status, which is an important determinant for the responsiveness to fluorouracil deriva…”
BackgroundInfluentialLiu, Y.-C., Yen, H.-Y., Chen, C.-Y., Chen, C.-H., Cheng, P.-F., Juan, Y.-H., Chen, C.-H., Khoo, K.-H., Yu, C.-J., Yang, P.-C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107385108 · Cited by 424 · cited 1×
“Thereafter, the Wong group reported that EGFR is hypersialylated in human lung cancer; furthermore, higher sialylation was found in invasive lung cancer, and sialylation was shown to regulate EGF-mediated receptor dimerization and EGFR phosphorylation in lung cancer cells.(146) The authors identified various sialylate…”
BackgroundCore Fucosylation Regulates Epidermal Growth Factor Receptor-mediated Intracellular Signaling
Wang, X., Gu, J., Ihara, H., Miyoshi, E., Honke, K., & Taniguchi, N. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510893200 · Cited by 323 · cited 1×
“The Taniguchi and Nishio groups both reported that fucosylation of EGFR at 10 N-glycosylation sites of its extracellular domain was essential for EGFR activity and EGFR-mediated survival signaling.(144,145) Thereafter, the Wong group reported that EGFR is hypersialylated in human lung cancer; furthermore, higher sialy…”
Background
Cited by
Glycosylation in health and disease
Reily, C., Stewart, T. J., Renfrow, M. B., & Novak, J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0129-4 · Cited by 2,075
Insights into the role of sialylation in cancer progression and metastasis
Dobie, C., & Skropeta, D. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01126-7 · Cited by 348
Pathological Unfoldomics of Uncontrolled Chaos: Intrinsically Disordered Proteins and Human Diseases
Uversky, V. N., Davé, V., Iakoucheva, L. M., Malaney, P., Metallo, S. J., Pathak, R. R., & Joerger, A. C. (2014) · Chemical Reviews · doi:10.1021/cr400713r · Cited by 288
Role of protein glycosylation in cancer metastasis
Oliveira-Ferrer, L., Legler, K., & Milde-Langosch, K. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.002 · Cited by 273
Darling, A. L., & Uversky, V. N. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00158 · Cited by 267
Metadata
- Authors
- Park, J.-J., & Lee, M.
- Venue
- Gut and Liver
- Published
- 2013-11-15
- Volume
- 7
- Issue
- 6
- Pages
- 629-641
- ISSN
- 1976-2283 (ISSN-L)
- 2005-1212
- OpenAlex
- W2067607506
- Cited by
- 123
- References
- 7
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increasing the α 2, 6 Sialylation of Glycoproteins May Contribute to Metastatic Spread and Therapeutic Resistance in Colorectal Cancer. https://app.cochat.ai/papers/10.5009/gnl.2013.7.6.629
- The paper
- Park, J.-J., & Lee, M. (2013). Increasing the α 2, 6 Sialylation of Glycoproteins May Contribute to Metastatic Spread and Therapeutic Resistance in Colorectal Cancer. Gut and Liver. https://doi.org/10.5009/gnl.2013.7.6.629
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.